Wohlfarth Kai, Sycha Thomas, Ranoux Danièle, Naver Hans, Caird David
Department of Neurology, BG Kliniken Bergmannstrost, Halle/S., Germany.
Curr Med Res Opin. 2009 Jul;25(7):1573-84. doi: 10.1185/03007990903028203.
The units of different preparations of botulinum neurotoxin type A (BoNT-A) have different potencies, and dosing recommendations for each product are not interchangeable. Historically, there has been debate concerning the dose-equivalence ratio that should be used in clinical practice.
Published evidence was considered to establish an appropriate dose-conversion ratio for the two main commercially available preparations of BoNT-A--Dysport (Dp) and Botox (Bx).
Four key areas of evidence were identified: nonclinical and preclinical studies; studies exploring the diffusion characteristics and effects of complexing proteins; comparative experimental data from human studies; and clinical studies. Nonclinical data indicate that the principal reasons for differences in unit potency between the two products are dilution artefacts in the mouse assay. Use of saline as a diluent, at high dilutions, results in significant loss of potency in the Bx assay, whereas use of gelatin phosphate buffer in the Dp assay procedure protects the toxin during dilution. The published data on mouse assays show a Dp : Bx unit ratio range of 2.3-2.5 : 1 in saline and 1.8-3.2 : 1 in gelatin phosphate buffer. Data indicate that complexing proteins or size of the complex, which is highly pH sensitive, play no role in toxin diffusion and that Dp and Bx have similar diffusion characteristics when used at comparable doses. Randomized, controlled clinical studies indicate that 3 : 1 is more appropriate than 4 : 1, but the two products are not equivalent at this ratio. Comparative human experimental studies using the extensor digitorum brevis test, facial lines and anhidrotic action halo tests support dose-conversion ratios less than 3 : 1.
Data comparing dose equivalence ratios from the non-clinical setting should be extrapolated into the clinical setting with some caution.
Dose-conversion ratios between Dp and Bx of 4 : 1 and greater are not supported by the recent literature.
不同A型肉毒杆菌神经毒素(BoNT-A)制剂的单位效力不同,每种产品的给药建议不可互换。历史上,关于临床实践中应使用的剂量等效比一直存在争议。
考虑已发表的证据,为两种主要的市售BoNT-A制剂——Dysport(Dp)和保妥适(Bx)确定合适的剂量转换比。
确定了四个关键证据领域:非临床和临床前研究;探索复合蛋白扩散特征和作用的研究;人体研究的比较实验数据;以及临床研究。非临床数据表明,两种产品单位效力存在差异的主要原因是小鼠试验中的稀释假象。在高稀释度下使用生理盐水作为稀释剂,会导致Bx试验中效力显著损失,而在Dp试验过程中使用明胶磷酸盐缓冲液可在稀释过程中保护毒素。已发表的小鼠试验数据显示,在生理盐水中Dp:Bx单位比范围为2.3 - 2.5:1,在明胶磷酸盐缓冲液中为1.8 - 3.2:1。数据表明,对pH高度敏感的复合蛋白或复合物大小在毒素扩散中不起作用,且Dp和Bx在可比剂量下具有相似的扩散特征。随机对照临床研究表明,3:1比4:1更合适,但在此比例下两种产品并不等效。使用趾短伸肌试验、面部皱纹和无汗作用晕圈试验的人体比较实验研究支持小于3:1的剂量转换比。
将非临床环境中比较剂量等效比的数据外推到临床环境时应谨慎。
近期文献不支持Dp和Bx之间4:1及更高的剂量转换比。